IMRN

IMRN

USD

Immuron Limited American Depositary Shares

$1.793-0.022 (-1.229%)

リアルタイム価格

Healthcare
バイオテクノロジー
オーストラリア

価格チャート

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$1.815

高値

$1.870

安値

$1.739

出来高

0.00M

企業ファンダメンタルズ

時価総額

10.3M

業種

バイオテクノロジー

Australia

取引統計

平均出来高

0.01M

取引所

NCM

通貨

USD

52週レンジ

安値 $1.6現在値 $1.793高値 $2.87

AI分析レポート

最終更新: 2025年4月27日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

IMRN: Immuron Limited American Depositary Shares - What's Happening and What to Watch

Stock Symbol: IMRN Generate Date: 2025-04-27 00:24:53

Let's break down what's been going on with Immuron lately and what the data might be hinting at.

The Latest Buzz: Sales Hit a High Note

The big news hitting the wires recently, specifically around April 10th, was all about sales. Immuron announced that their global sales, driven by their Travelan product, crossed the AUD$5 million mark for the fiscal year. That's a record high for the company.

What does this mean? Well, hitting record sales is generally a really positive sign. It tells us that their main product, Travelan, is finding more customers and bringing in more money than ever before. The March quarter sales were also up slightly year-over-year. This kind of news usually creates a good feeling around a stock – it suggests the business is growing and executing well.

Checking the Stock's Pulse: Price Action

Looking back at the last few months of trading data, Immuron's stock price has been quite a ride. It's bounced around, showing a good bit of volatility. We saw prices dip down towards the $1.60 level recently, which happens to be near its 52-week low.

Around the time that positive sales news came out in early April, the stock did see some increased activity and a bit of a bump up from those lower levels. However, it hasn't held onto all of those gains and has settled back into the $1.70 to $1.80 range in the last few days of the data provided. The previous day's close was $1.79.

Now, what about the very near future? The AI prediction model suggests things might stay pretty flat today (0.00% change), maybe dip slightly tomorrow (-0.95%), and then tick up a tiny bit the day after (0.36%). These are very small predicted moves, suggesting the AI doesn't see a big swing coming right away based on its patterns.

Putting It Together: What Does This Picture Suggest?

Considering the positive news about record sales, which is a strong fundamental point, alongside a stock price that's been trading near its recent lows and the AI predicting relatively flat movement short-term, what's the takeaway?

The record sales news is definitely a point in the company's favor. It shows real business progress. The stock price, however, hasn't fully reflected that with a sustained upward move yet, perhaps due to overall market conditions or other factors. The AI's short-term forecast is pretty neutral.

Based strictly on this combination of factors – good news, a price near recent lows, and flat short-term predictions – the situation might lean towards a 'Hold' or potentially 'Accumulate' for those interested, rather than a clear 'Sell'. The positive sales are a fundamental tailwind, even if the price hasn't rocketed up immediately.

Potential Entry Consideration: If someone were considering getting in, the current price area, perhaps around the $1.70 to $1.80 range where it's been trading recently, could be looked at. This is above the 52-week low and aligns somewhat with the AI's flat short-term view, suggesting it's not expected to plummet immediately based on that model. Some might even eye a dip closer to the $1.69 level mentioned in the recommendation data as a potential entry point if it pulls back slightly.

Potential Exit/Stop-Loss Consideration: Managing risk is always key. If the stock were to fall below its recent lows, say under $1.60 (the 52-week low and close to the $1.61 stop-loss level mentioned in the recommendation data), that might be a point where some investors would consider cutting losses. On the upside, if the positive news starts to gain more traction and the stock moves up, a potential target for taking profits mentioned in the recommendation data is $2.36.

A Little More Context

Remember, Immuron is a small biopharma company focused on specific products like Travelan. It only has 7 full-time employees and a market cap of around $10 million. Stocks this small can be quite volatile, and trading volume can be low, which means prices can sometimes move sharply on relatively small amounts of buying or selling. The record sales are significant for a company of this size.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are risky, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

関連ニュース

GlobeNewswire

Immuron Travelan® highest sales in history

Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2% on prior yearMarch 2025 Year to Date AUD$5.3 million up

もっと見る
Immuron Travelan® highest sales in history

AI予測Beta

AI推奨

弱気

更新日時: 2025年4月28日 12:49

弱気中立強気

57.2% 信頼度

リスクと取引

リスクレベル4/5
高リスク
適しているのは
バリュー成長アグレッシブ
取引ガイド

エントリーポイント

$1.69

利確

$2.36

損切り

$1.61

主要因子

PDI 46.1はMDI 41.7の上にあり、ADX 5.8とともに強気トレンドを示唆しています
MACD 0.0105はシグナルライン0.0075の上にあり、強気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。